Stock Research: Adaptive Biotechnologies

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Adaptive Biotechnologies

NasdaqGS:ADPT US00650F1093
63
  • Value
    12
  • Growth
    79
  • Safety
    Safety
    22
  • Combined
    22
  • Sentiment
    100
  • 360° View
    360° View
    63
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Adaptive Biotechnologies Corporation is a biotechnology company focused on harnessing the adaptive immune system for disease diagnosis and treatment. It operates in the fields of Minimal Residual Disease (MRD) with its clonoSEQ clinical diagnostic test, and Immune Medicine, discovering and developing immune-based therapies for cancer and autoimmune diseases. In the last fiscal year, the company had 619 employees, a market cap of $1701 million, profits of $107 million, and revenue of $179 million.

more
Index
NASDAQ
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 18-Dec-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
12 6 55 25
Growth
79 99 71 29
Safety
Safety
22 8 98 87
Sentiment
100 80 57 47
360° View
360° View
63 47 94 21
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
83 64 67 42
Opinions Change
50 28 50 50
Pro Holdings
n/a 82 39 83
Market Pulse
86 75 49 26
Sentiment
100 80 57 47
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
12 6 55 25
Growth
79 99 71 29
Safety Safety
22 8 98 87
Combined
22 19 94 56
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
60 60 60 10
Price vs. Earnings (P/E)
23 39 59 17
Price vs. Book (P/B)
14 4 60 55
Dividend Yield
1 1 1 1
Value
12 6 55 25
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
21 91 88 70
Profit Growth
75 60 61 28
Capital Growth
81 88 58 70
Stock Returns
91 95 21 9
Growth
79 99 71 29
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
31 30 100 100
Refinancing
35 23 75 49
Liquidity
25 28 26 n/a
Safety Safety
22 8 98 87

Similar Stocks

Discover high‑ranked alternatives to Adaptive Biotechnologies and broaden your portfolio horizons.

Micron

NasdaqGS:MU
Country: USA
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Cognizant Technology

NasdaqGS:CTSH
Country: USA
Industry: IT Consulting & oth. Services
Size: X-Large
Full Stock Analysis

Alphabet

NasdaqGS:GOOG.L
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Frequently Asked
Questions

This is a classic, high-risk growth play: high growth and positive sentiment outweigh low Value Rank (expensive) and risky financing. This is for aggressive growth investors who are comfortable with the high price and risk, believing the growth story justifies the expense.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: